BIG QUESTION ?????....Why is it that when debbie downers write about TLT, they never talk about TLT great achievements?
1) TLT data are superior to all FDA approved treatments for BCG resistant patients.
2) TLT-Ruvidar Duration Of Response data are also superior to anything out there (including TLT future competitors).
3) TLT treatment treat patients that no other FDA approved treatments can treat. Because of this TLT is not competing with other FDA approved treatments.
4)Unlike all the other FDA approved treatments, TLT-Ruvidar has no restrictions and is 100% safe(''We treat all patients, all comers, and our data are world class'').
5)The scientific community is beginning to recongnize TLT-Ruvidar as a success story.
6) Because ot its mechanism of action, TLT treatment will be applicable to almost all cancer types(200 Cancer types).
7) TLT future pipeline is huge, starting with Rutherrin. Rutherrin has been show to be effective across numerous potential applications.
-Bladder cancer.
-Immunotherapy.
-Chemotherapy.
-Non small lung cancer.
-Brain cancer.
-Numerous virus.
-ETC....
8) Because TLT is treating patients that no other FDA approved treatments can treat, the FDA badly need TLT-Ruvidar for Unmett Medical Needs(BTD is for Unmett Medical Needs).
Yes the innovative aspect of TLT-Ruvidar is slowing down the FDA approval process,but on the long term, the patients and TLT investors will win big time.
I love the huge upside potential of TLT treatments.
And...
I love my TLT shares.
.